An open label, long-term treatment evaluation of the safety of BEMA [BioErodible MucoAdhesive] fentanyl use for breakthrough pain in cancer subjections on chronic opioid therapy
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2012
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors BioDelivery Sciences International
- 14 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
- 14 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
- 17 Oct 2006 New trial record.